Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neoadjuvant chemotherapy of S-1/OXaliplatin for locally advanced Gastric cancer PI

Trial Profile

Neoadjuvant chemotherapy of S-1/OXaliplatin for locally advanced Gastric cancer PI

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Jun 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin
  • Indications Gastric cancer
  • Focus Adverse reactions
  • Acronyms Neo G-SOX PI study
  • Most Recent Events

    • 17 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 02 Jun 2017 Results (n=12) of an integrated analysis on quality of life of oxaliplatin-based preoperative chemotherapy for locally advanced gastric cancer assessment from UMIN000015950 and UMIN000015181 studies, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 26 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top